

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Eric Thwaites

Confirmation No: 3883

Serial No.: 10/734,432

Group Art Unit: 1657

Filed: December 12, 2003

Examiner: C. Petersen

For: Flocculation With Divalent Salt

**INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(b)**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed.

Additional Information

This application is a continuation-in-part of U.S. application no. 10/463,919. During prosecution of the parent application, the Office issued an action mailed September 11, 2006 rejecting claims 1-8 under 35 U.S.C. 103 as being obvious over the teachings of Abdo (U.S. Patent No. 3,711,462) and Weigel et al. (EP 1522579). Applicants submit that the claims pending in this application are patentable over Abdo and Weigel et al.

It is respectfully requested that these references and the file history of the parent application be considered by the USPTO in its examination of the above-identified application and be made of record therein.

This IDS is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: November 16, 2007

/Elias Lambiris, Reg. # 33728/  
Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097